Table 1 Baseline characteristics

	High dose (n = 24)	Low dose (n = 24)	Control (n = 24)	p Value
Site [n (%)]
Beijing	7 (29.17%)	6 (25.00%)	6 (25.00%)	0.931^b
Yunnan	8 (33.33%)	7 (29.17%)	7 (29.17%)	0.937^b
Xinjiang	6 (25.00%)	7 (29.17%)	8 (33.33%)	0.817^b
Guangzhou	3 (12.50%)	4 (16.67%)	3 (12.50%)	0.890^b
Age (years)	42.0 (33.3, 48.0)	42.5 (38.0, 45.8)	41.5 (35.5, 48.8)	0.959^a
No. of male/female (n)	19/5	19/5	19/5	>0.999^b
Weight (Kg)	59.0 (55.3, 65.0)	65.0 (55.3, 70.0)	61.0 (57.0, 63.9)	0.323^a
BMI	20.80 ± 2.04	22.06 ± 2.04	21.40 ± 2.11	0.115^a
Route of HIV infection [n (%)]
Sexual	20 (83.33%)	16 (66.67%)	16 (66.67%)	0.330^b
Blood/Injection drug use	2 (8.33%)	2 (8.33%)	1 (4.17%)	0.807^b
Other or unknown	2 (8.33%)	6 (25.00%)	7 (29.17%)	0.171^b
Diagnosis time (years)	4.13 (2.35, 5.23)	3.25 (2.92, 4.40)	3.58 (2.58, 5.71)	0.803^a
ART time (years)	3.38 (2.12, 4.25)	3.13 (2.58, 4.06)	3.17 (2.29, 4.96)	0.739^a
Viral load < 50 copies per mL (%)	100%	100%	100%	>0.999^b
CD4 counts (cell/μL)	179 (144, 224)	181 (149, 200)	179 (161, 209)	0.935^a
CD8 counts (cell/μL)	733 (476, 878)	558 (400, 868)	623 (466, 835)	0.509^a
CD4/CD8 ratio	0.29 (0.17, 0.35)	0.31 (0.20, 0.41)	0.29 (0.20, 0.45)	0.639^a
First-line drugs [n (%)]
AZT + 3TC + NVP/EFV	13 (54.17%)	11 (45.83%)	11 (45.83%)	0.801^b
D4T + 3TC + NVP/EFV	7 (29.17%)	6 (25.00%)	8 (33.33%)	0.817^b
TDF + 3TC + NVP/EFV	2 (8.33%)	6 (25.00%)	3 (12.50%)	0.248^b
Other	2 (8.33%)	1 (4.17%)	2 (8.33%)	0.807^b

The data for age, weight, diagnosis time, ART time, CD4 counts, CD8 counts, CD4/CD8 ratio are the median (interquartile range [IQR]). The BMI is shown as the mean ± SE; other data are shown as n (%).
3TC lamivudine, TDF tenofovir, D4T stavudine, EFV efavirenz, NVP nevirapine.
^aP value of continuous data between three groups: Kruskal–Wallis test or one-way ANOVA t test.
^bP value of categorical data between three groups: Pearson χ² test or Fisher’s exact test (two-tailed).

Quick links

Search